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agement of such patients.
Conclusion: The repatriation of men with stable prostate cancer is largely
preferred by patients. There is a need for greater patient and GP education
with clear protocols available to give conﬁdence to all parties in follow-up
care.http://dx.doi.org/10.1016/j.ijsu.2016.08.467
0715: VISIBE HAEMATURIA DUE TO UTI e DOES IT NEED
INVESTIGATING?
B. Starmer*, A. Singh, S. Bromage. Stockport NHS Foundation Trust, Stockport,
UK.
Aim: It is well documented that UTI can cause visible haematuria (VH).
Current NICE guidelines suggest that VH secondary to UTI does not need
investigating. While this is intuitive, it is not based on any evidence. We
aim to establish any evidence towards or against this approach.
Method: Retrospective review of casenotes.
Result: There were 599 patients with VH. 299/599 had a negative urinal-
ysis for blood on the day of haematuria clinic. 302/599 had a recorded
MC+S in the 6 weeks prior to ﬂexible cystoscopy. 63/302 patients had a
positive culture on MC+S. 1/63 patient in this group was shown to have a
T1b left renal cell carcinoma. This patient had a positive dipstick on the day
of their haematuria clinic. No bladder tumours were found. 0/29 of those
who had a positive MC+S followed by a negative urinalysis on the day of
haematuria clinic were found to have cancer.
Conclusion: Here, we provide evidence that UTI with VH that has been
treated and has negative urinalysis following this requires no haematuria
investigations. We still advise that persisting non-visible haematuria
following treatment for UTI is investigatedhttp://dx.doi.org/10.1016/j.ijsu.2016.08.468
0793: VENOUS THROMBOEMBOLISM RISK SCORES IN UROLOGICAL PA-
TIENTS: A COMPARISON OF DIFFERENT SCORING METHODS
M. Karia*, S. Onida, A. Davies. Imperial College London, London, UK.
Aim: 1-5% of patients undergoing major urological surgery experience
symptomatic venous thromboembolism (VTE), with pulmonary embolism
(PE) the most common cause of post-operative death. The Caprini and
Department of Health (DoH) scores are assessment systems estimating
VTE risk and the requirement for pharmacological thromboprophylaxis.
The aim of this study was to assess the agreement between these two
assessment methods in urology patients.
Method: 78 patients undergoing urological procedures were prospectively
risk assessed using the Caprini and DoH VTE score and categorized into
low, medium or high risk. Inter-rater agreement was assessed using
Cohen's Kappa coefﬁcient.
Result: There was a 73% agreement between the two scoring methods.
Cohen's kappa coefﬁcient was 0.571 indicating ‘moderate agreement'. Of
the 21 patients where therewas a disagreement, 6 were categorized as low
risk according to one score (3 DoH, 3 Caprini) and medium risk according
to the second score.
Conclusion: We demonstrate a ‘moderate agreement' between scoring
methods in urological patients. The disagreement between low/medium
scoring is clinically relevant, as these patients would have only been pre-
scribed pharmacological thromboprophylaxis depending on the scoring
system used. Further research efforts are required to assess the impact of
differences in these scoring systems in this patient cohort.http://dx.doi.org/10.1016/j.ijsu.2016.08.469
0842: PROSTATIC MEMOKATHS. A LONG-TERM FOLLOW UP OF 35
CASES
C. Mosli-Lynch, N. Chari, L. Forster, C. Tanabalan, P. Patki. St Bartholomew's
Hospital, LONDON, UK.Objective: To examine the long-term efﬁcacy of an expanding metallic
stent (Memokath) placed in patients with obstruction of the prostatic
urethra who were unﬁt or unsuitable for surgical intervention, in order to
determine a population of patients in whom a prostatic memokath would
be a suitable treatment.
Method: We followed up 35 patients who had a prostatic Memokath
placed in a single unit between 2005 and 2009 to assess their long-term
functional outcome. Aside from demographic factors and reason for
insertion we looked at migration rate, replacement rate and survival
times.
Result: Themean age at insertionwas 78.13 patients are still alive with the
Memokath in situ (mean time 86.3 months). 9 patients died with the
Memokath in situ, mean survival time: 29.3months (range 1-69). In eleven
patients the Memokath either migrated (5) or was removed (6) with a
mean time of 3.7 months (range 5 days- 11 months). Two patients were
lost to follow up.
Conclusion: Prostatic Memokaths are useful in patients who are unable to
tolerate either a GA or a LASER resection of the prostate, and who have a
reasonable life expectancy. Though a proportion either migrate or neces-
sitate removal, the majority are well tolerated.http://dx.doi.org/10.1016/j.ijsu.2016.08.470
0930: INITIAL EXPERIENCE OF PROSTATIC URETHRAL LIFT (UROLIFT); A
MINIMALLY INVASIVE TREATMENT FOR SYMPTOMATIC BENIGN PROS-
TATIC HYPERPLASIA
S. Hulligan*, E. Johnson, R. Mistry, H. Gana. Whiston Hospital, Merseyside,
UK.
Introduction: The UroLift procedure in treating LUTS secondary to BPH
has recently been accredited by NICE (September-2015) for men over
50years, with prostates under 100ml without an obstructing middle
lobe. The system avoids the risk to sexual function associated with
current gold standard of TURP, & HoLEP. Initial outcome experience of
Urolift.
Method: Patients assessed both prospectively and retrospectively. Vari-
ables analysed included; pre/post-procedure IPSS, QoL, erectile and ejac-
ulation function. Patients were assessed periodically post-procedure to
evaluate initial outcomes.
Result: 13 Urolift procedures analysed. Mean 65years(range 58-77), all
failed medical management(13). Prostates size 25g-85g, mean PSA 1.66ug/
l. Pre-procedure Qmax mean 13.86ml/sec. All were day-case procedures,
no post-procedure urinary retention, no signiﬁcant adverse effects.
During 1-8months follow up; IPSS mean improved; 20.1(7-31) pre-pro-
cedure to 6.5(1-16) post-procedure(67.7%symptom reduction). QoL score
improved 4.3(2-6)to 1.4(1-6). No QoL improvement in one patient, one
patient 4month delayed improvement due to persistent storage
symptoms.
Post-procedure zero patients experienced retrograde ejaculation. Zero
experienced new erectile dysfunction(ED). 6 had ED prior, zero reporting
deterioration, two reporting improvement.
Conclusion: Urolift is a safe, efﬁcacious treatment of BPH LUTs in the short
term, with a reduction in length of hospital stay. Longer term data will
follow. Preservation of tissue structures ensures sustained sexual function.http://dx.doi.org/10.1016/j.ijsu.2016.08.471
0953: REDUCING THE RISK OF BOWEL INJURY IN OUR NURSE-LED
OUTPATIENT SUPRAPUBIC CATHETER CLINIC
E. Papworth*, R. MacDonagh, A. MacCormick, R. Bamford. Musgrove Park
Hospital, Taunton, UK.
Aim: Rarely, suprapubic catheter insertion is associated with the risk of
bowel perforation. We assessed risk of bowel injury both before and after
the introduction of ultrasound scanning (USS) as an adjunct to SPC
insertion.
Method: A dedicated SPC clinic was established in July 2008, undertaken
by a formally structurally trained specialist nurse.
Abstracts / International Journal of Surgery 36 (2016) S31eS132 S127From April 2013, pre-procedural USS was carried out on each patient
attending for SPC insertion. Patients with overlying bowel were referred
for open insertion.
Result: 322 SPCs were inserted between July 2008 e April 2013 without
the routine use of pre-procedural USS. 101 were inserted between May
2013- June 2015 with USS guidance.
Following the introduction of USS, there were no recorded cases of bowel
perforation associated with SPC insertion (Without USS 3/322, 0.9%, with
USS 0/101, 0%). Referrals for open insertion increased (Without USS 7/322
(2.6%), with USS 12/101 (12%)).
Conclusion: In our clinic, use of pre-procedural USS has eliminated the
risk of associated bowel perforation, with an appropriate increase in re-
ferrals for open insertion.
Dedicated SPC clinics provide a safe and effective service for SPC insertion
with excellent opportunities for training.http://dx.doi.org/10.1016/j.ijsu.2016.08.472
0962: IS THERE A ROLE FOR ORCHIDECTOMY IN THE MANAGEMENT OF
REFRACTORY CHRONIC TESTICULAR PAIN
H. Garrod*, G. Brown. Royal Glamorgan Hospital, Llantrisant, UK.
Aim: Chronic testicular pain represents a difﬁcult challenge for the urol-
ogist and has a varied aetiology. Around 25% of patients will not have a
cause identiﬁed for their symptoms but continue to experience debili-
tating pain. When pain is refractory to pharmaceutical treatment, patients
may be referred for consideration of orchidectomy. We aim to assess the
effectiveness of this procedure.
Method: Eight patients who underwent an orchidectomy for chronic
testicular pain were retrospectively reviewed. A telephone follow-up was
conducted to assess post-operative pain outcomes.
Result: Average age was 44 years. 88 % said their pain improved, 62 %
reorted complete resolution. The mean improvement in all patients was
65%. Only one patient felt there had been no improvement in their pain.
There was no consistent singular histological ﬁnding although half of pa-
tients showed evidence of ﬁbrosis or atrophy. One patient felt that their
pain had not improved and felt there had been additional sexual and
psychological problems that outweighed the beneﬁts of surgery.
Conclusion: This study supports other data that orchidectomy is an
effective treatment in refractory chronic testicular pain. Careful patient
selection is paramount and further research is required to identify patients
most likely to beneﬁt from this procedure.http://dx.doi.org/10.1016/j.ijsu.2016.08.473
0970: SURGICAL OUTCOME ANALYSIS OF 130 CONSECUTIVE PARTIAL
NEPHRECTOMIES UNDERTAKEN IN THE SOUTH WALES REGION AND
COMPARISON WITH BAUS (STUKA) DATA
D. Teichmann 1,*, L. Whitehurst 1, R. Chaytor 2, I.l Omar 3, O. Naser 3,
M. Kamarizan 4, A. Carter 4, S. Moosa 3, K. Narahari 1, R. Coulthard 1,
N. Fenn 2. 1University Hospital of Wales, Cardiff, UK; 2Morriston Hospital,
Swansea, UK; 3Glangwili General Hospital, Carmarthen, UK; 4Royal Gwent
Hospital, Newport, UK.
Aim: Partial Nephrectomy is an increasingly popular technique for man-
aging small renal tumours both via an open and laparoscopic approach.We
wished to compare our regional numbers, approaches and complication
rates to the nationally published BAUS STUKA audit
Method: We performed a retrospective case-note analysis across 4
regional centres of 130 consecutive partial nephrectomies between the
years of 2011-2015. We examined patient demographics, surgical
approach, operation time, blood loss, warm/cold ischaemia time, tumour
histology, margin positivity, length of stay and complication rates as
classiﬁed by the Clavien-Dindo system (CD)
Result: Our results compare favourably with the STUKA audit in the do-
mains of post-operative complications as classiﬁed by CD 2-5 (10% vs 13%).
A lower percentage of cases are done laparoscopically (14% vs 24% na-
tionally) despite tumour size distribution being similar. Margin positivitywas similar laparoscopically (5.5%), although higher than the national
average in open cases (10.7% vs 5%). Malignant disease was 6% lower (81%
vs 87%) and benign disease was 7% higher (11% vs 18%). There were no
patient deaths and no recorded recurrences at present.
Conclusion: We believe this practice evaluation provides the foundation
for service development. Varied numbers between units favour central-
isation of care thus allowing development in laparoscopic techniques
including the recently acquired robotic service.http://dx.doi.org/10.1016/j.ijsu.2016.08.474
1039: SHOULD WE RECONSIDER RUSHING TO CONVERT NEPHROSTO-
MIES TO ANTEGRADE STENTS IN THE PALLIATIVE SETTING?
L. Chandra*, P. Hughes, M. Kimuli. Leeds Teaching Hospitals Trust, West
Yorkshire, UK.
Introduction: The management of ureteric obstruction in the palliative
care setting is potentially challenging. Clinicians often deliberate long and
hardwith patients and family regarding the implications of their prognosis
and the role of nephrostomies in alleviating renal failure. However, sub-
sequent conversion to an antegrade stent is often regarded as a default
procedure, but perhaps may not always appropriate for patients with very
limited lifespans.
Method: We performed a retrospective review of all antegrade stents
inserted (2011-14) as a consequence of malignancy within our institution.
Demographics, primary malignancy, disease stage and treatments to date
were detailed along with survival duration post stent insertion.
Result: 73.5% of patients receiving ‘best supportive care' died within 90
days of antegrade stent insertion. For patients receiving curative or palli-
ative treatment this was only 12.5% and 21% respectively.
Conclusion: Recognising the limited lifespan that patients considered for
best supportive care have, clinicians should consider the need and
appropriateness of a second invasive procedure to insert an antegrade
stent. This study can help inﬂuence quality of life discussions with patients
who face the ﬁnal phases of their lives.http://dx.doi.org/10.1016/j.ijsu.2016.08.475
1163: THE INTRODUCTION OF MULTIPARAMETRIC MRI IN PROSTATE
CANCER MANAGEMENT: DOES IT AID THE UROLOGIST?
D. Loughran*, D. Teichmann, P. Bose, J. Featherstone, S. Davies, R. Evans,
N. Fenn. Morriston Hospital, Swansea, UK.
Aim: NICE prostate cancer guidelines recommend the use of multi-para-
metric MRI in patients undergoing i) active surveillance or ii) those with a
raised PSA wishing to avoid initial or repeat biopsy. We examine man-
agement outcomes in these groups following the introduction of our new
3T mpMRI Service.
Method: Patients were categorised as either; being on or considered for
Active Surveillance (n¼29), or patients being investigated for a raised PSA,
either biopsy naïve (n¼11) or with previous biopsies (n¼13).
Result: In the ‘active surveillance’ group, mpMRI allowed 83% (n¼24) to be
reassured of low volume disease with 10% (n¼3) requiring further inves-
tigation with a targeted biopsy (7%, n¼2) or bone scan (3%, n¼1) Two
patients underwent deﬁnitive management in the form of EBRT and
recruitment to a HIFU trial.
In the ‘biopsy naive’ group (n¼11), 10 were reassured and 1 underwent
targeted biopsy.
In the ‘previous biopsy group’ (n¼13), 10 were reassured, 2 underwent
targeted biopsy, the last was inconclusive due to THR's.
Conclusion: Adoption of NICE guidance on mpMRI indications allowed
evidence based decisions to be made regarding maintenance of AS, pre-
vention or initiation of targeted biopsy, or active treatment.http://dx.doi.org/10.1016/j.ijsu.2016.08.476
